Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLI

Authors

Michelle L. D’Antoni (ORCID: https://orcid.org/0009-0004-5395-7022)
Silvia D. Chang (ORCID: https://orcid.org/0000-0002-9201-8114)
Anchalee Avihingsanon (ORCID: https://orcid.org/0000-0003-3222-9611)
Archana V. Boopathy (ORCID: https://orcid.org/0009-0009-9164-0858)
Laurie A. VanderVeen
Kristen Andreatta
Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
Christian Callebaut (ORCID: https://orcid.org/0000-0003-4721-2572)

Institutions

Chulalongkorn University (TH)
HIV Netherlands Australia Thailand Research Collaboration (TH)
Gilead Sciences (United States) (US)

Publication Details

Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes
Published: 2025-08-26
DOI: https://doi.org/10.1097/qai.0000000000003749
Citations: 1
Primary Topic: HIV/AIDS drug development and treatment
Type: article
Field-Weighted Citation Impact: 1.40

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLI

Michelle L. D’Antoni, Silvia D. Chang, Anchalee Avihingsanon, Archana V. Boopathy et al.

Aug 26, 2025

1 citations

JAIDS Journal of Acquired Immune Deficiency Syndromes

HIV/AIDS drug development and treatment

1.40

article

Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLI

Michelle L. D’Antoni, Silvia D. Chang, Anchalee Avihingsanon, Archana V. Boopathy, Laurie A. VanderVeen, Kristen Andreatta, Jason T. Hindman, Christian Callebaut

August 26, 2025article en

1 citations

Abstract

No abstract available for this paper.

JAIDS Journal of Acquired Immune Deficiency SyndromesVol. 100(4)

Chulalongkorn University (TH), HIV Netherlands Australia Thailand Research Collaboration (TH), Gilead Sciences (United States) (US)

Good health and well-being

Openalex Percentile: Top 17%

HIV/AIDS drug development and treatment

1.40

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLI — Michelle L. D’Antoni, Silvia D. Chang, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes (2025) | TGRS Research Map | TGRS